Palliative Nierentumorembolisation mittels Jodöl-markiertem Ethibloc^®

Abstract

In 59 patients having non-operable malignant renal tumours, palliative trans-catheter embolization was performed. In 42 of them follow-up observations were realized over 18 months. The average survival rate was then 43% of cases. Local tumour growth was documented in 9 patients (23%) due to recanalization of the embolized arteries (13%) and to non-occluded collateral vessels (10%). The choice of suitable embolizing materials mainly influences the therapeutic result: Oily contrast labeled amino-acid Ethibloc is considered to be the material of choice for safe application and reliable vascular distribution causing persisting occlusion of the renal arteries.

Präoperative und palliative Embolisation des Nierenzellkarzinoms: Nachsorge von 49 Patienten

“…In einer Studie von Weber traten in 5,9 % der Embolisationen (3 von 51 Patienten) schwere Komplikationen mit Materialreflux, passagere Beinparese und ileofemorale Venenthrombose mit foudroyanter Lungenembolie und anschließend Exitus letalis auf [21]. Durch den konsequenten Einsatz des Ballons kann der Anteil von Fehlembolisationen vermindert werden [16].…”

“…3). Unsere Patienten hatten im Durchschnitt das 5fache Tumorvolumen der Bakal-Studie mit 510 ml Blutverlust aller präoperativ embolisierten Patienten [21]. Es gibt bisher keinen Anhalt dafür, dass die präoperative Embolisation zu einer Reduzierung des intraoperativen Blutverlustes führt, da Vergleichsstudien fehlen.…”

Experimental Basis of Angioinfarction for the Treatment of Renal Hypertension

“…Therefore we performed several studies to enhance the radiodensity of Ethibloc [50]. The addi tion of different radiopaque substances, like Metrizamid or Lipiodol, proved to be dangerous [59]. They either interfere with precipitation resulting in incomplete vasoocclusion (Metrizamid due to its osmotic effect) or lead to pulmonary embolism (Lipiodol separating from precipi tated Ethibloc).…”